Teva announced the launch of AirDuo® Digihaler® (fluticasone propionate and salmeterol inhalation powder) and ArmonAir® Digihaler® (fluticasone propionate inhalation powder) for patients with asthma.
AirDuo Digihaler is a combination of fluticasone propionate, a corticosteroid, and salmeterol, a long-acting beta2-adrenergic agonist (LABA). It should be used in patients aged 12 years and older not adequately controlled on a long-term asthma control medication such as an inhaled corticosteroid (ICS) or whose disease warrants initiation of treatment with both an ICS and LABA.
ArmonAir Digihaler contains fluticasone, a corticosteroid. It is indicated for the maintenance treatment of asthma as prophylactic therapy in patients 12 years and older.
The AirDuo Digihaler is supplied in 3 strengths: 55/14 mcg, 113/14 mcg, and 232/14 mcg; each inhaler provides 60 actuations. The Wholesale Acquisition Cost (WAC) is $399 for the 55mcg/14mcg and 113mcg/14mcg doses and $449 for the 232 mcg/14 mcg dose.
The ArmonAir Digihaler is supplied in 3 strengths: 55 mcg, 113mcg, and 232 mcg; each inhaler provides 60 actuations. The WAC is $239 for the 55 mcg and 113 mcg doses and $299 for the 232 mcg dose.
Teva recently announced the availability of ProAir® Digihaler® for patients aged 4 years and older for the treatment or prevention of bronchospasm with reversible obstructive airway disease, and for the prevention of exercise-induced bronchospasm. The Company has also introduced a patient savings program for the Digihaler portfolio of products.
For more information visit tevapharm.com.
Teva launches two digital inhalers in the US, AirDuo® Digihaler® (fluticasone propionate and salmeterol) inhalation powder and ArmonAir® Digihaler® (fluticasone propionate) inhalation powder. https://www.businesswire.com/news/home/20200921005170/en/Teva-Launches-Two-Digital-Inhalers-in-the-U.S.-AirDuo%C2%AE-Digihaler%C2%AE-fluticasone-propionate-and-salmeterol-Inhalation-Powder-and-ArmonAir%C2%AE-Digihaler%C2%AE-fluticasone-propionate-Inhalation-Powder. Accessed September 21, 2020.
This article originally appeared on MPR